Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $122,374.85 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Los Pinos Elisabet De also recently made the following trade(s):

• On Tuesday, October 29th, Los Pinos Elisabet De sold 9,200 shares of Aura Biosciences stock. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00.

Aura Biosciences Trading Up 2.1 %

NASDAQ AURA traded up $0.16 during trading on Tuesday, hitting $7.93. The company had a trading volume of 109,434 shares, compared to its average volume of 130,195. Aura Biosciences, Inc. has a one year low of $6.63 and a one year high of $12.38. The company has a market cap of $396.10 million, a price-to-earnings ratio of -4.58 and a beta of 0.30. The company’s fifty day moving average is $8.55 and its 200-day moving average is $8.91.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. As a group, equities analysts anticipate that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Hedge Funds Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently modified their holdings of AURA. Rhumbline Advisers increased its holdings in shares of Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after acquiring an additional 18,011 shares in the last quarter. American Century Companies Inc. bought a new stake in shares of Aura Biosciences during the second quarter valued at approximately $119,000. Dimensional Fund Advisors LP increased its holdings in Aura Biosciences by 20.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after buying an additional 41,711 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Aura Biosciences by 26.3% in the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after buying an additional 15,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after buying an additional 8,194 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Scotiabank boosted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. BTIG Research boosted their target price on Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.